High incidence of hyperventilation syndrome after COVID-19.

Competing Interests: Conflict of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-2753). Dr. JT reports meeting from Vitalair, outside the submitted work. Dr. HS reports grants from Foch Foundation, grants from Foundation pour la Recherche en Sante respiratoire, grants from Philippe Foundation, personal fees from LVL medical, personal fees from GSK, personal fees from Oxyvie, outside the submitted work. Dr. NB reports meal from Fresenius Kabi France, meal from MERZ Pharma France, personal fees from MEDTRONIC SAS, outside the submitted work. Dr. CG reports meeting from oxyvie, meeting from SOS oxygene, outside the submitted work. Dr. AC reports personal fees and meeting room Boehringer Ingelheim, meeting from LVL medical, meeting from Homeperf, grants and personal fees from Astra ZENEKA, outside the submitted work. Dr. EC reports meeting from LVL medical, meeting from SOS oxygène, meeting from CSC Bearing, personal fees from INsmed, outside the submitted work. Dr. LJC reports personal fees and meeting from Astra Zeneca, personal fees and meeting from Boehringer Ingelheim, meeting from LVL medical, meeting from Elivie, outside the submitted work. Dr. CT reports personal fees and meeting from Laboratoire GlaxoSmithKline, hospitality from LVL Medical, personal fees and hospitality from AstraZeneca, personal fees and hospitality from Boehringer France, hospitality from Novartis Pharma, outside the submitted work. The other authors have no other conflicts of interest to declare.